LVTX(Delisted)
LAVA Therapeutics·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 2
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LVTX
Lava Therapeutics N.V.
A clinical-stage immuno-oncology company that develops new cancer treatments that leverage the immune system
Yalelaan 62, 3584 CM Utrecht, The Netherlands
--
LAVA Therapeutics N.V. was incorporated in the Netherlands on February 15, 2016. The company is a clinical-stage immuno-oncology company dedicated to the rapid development of new cancer treatments that harness the immune system to save patients' lives. Utilizing the company's Gammabody platform, the company is developing a series of novel bispecific antibodies designed to harness the potency and precision of γ-δ (gd) T cells to elicit a powerful natural anti-tumor immune response and improve the prognosis of cancer patients.
Company Financials
EPS
LVTX has released its 2025 Q3 earnings. EPS was reported at -0.27, versus the expected -0.23156, missing expectations. The chart below visualizes how LVTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
